
Johannes Brägelmann
@braegelmannlab
Physician & biostatistician. Excited about cancer research, tumor evolution & functional genomics, driven to improve cancer therapy
ID: 1431003907812204545
http://www.braegelmannlab.com 26-08-2021 21:21:56
144 Tweet
116 Takipçi
150 Takip Edilen


Very happy to share our letter published European Urology ➡️Membranous expression of target protein is required for ADC response in urothelial cancer sciencedirect.com/science/articl… Thanks to the great co-authors Markus Eckstein Christoph Kuppe Johannes Brägelmann Viktor Grünwald




😱 Don't get spooked by new data - watch the #UromigosLive24 panel on novel ADCs in urothelial carcinoma discussed by Tom Powles, Andrea Apolo, M.D., Petros Grivas, Shilpa Gupta, and KSridhar. 🔬 Learn about a new study from Dr. Yohann Loriot of Gustave Roussy on BT8009, HER3, and


Now online in Cancer Discovery: Sympathetic Neurons Promote Small Cell Lung Cancer Through the β2 Adrenergic Receptor - by Tala, Jianwen Que, and colleagues Columbia Medicine Herbert Irving Comprehensive Cancer Center doi.org/10.1158/2159-8… #CancerNeuroscience #SCLC



Significant data from Niklas Klümper and team on Zelenectide in heavily pretreated breast cancer patients with Nectin-4 amplification showing an ORR of 57.1% Bicycle Therapeutics


ASCO25 Zelenectide vedotin (BT8009) + pembro: ORR 65% (25% CR) in 1L cis-ineligible la/mUC (incl. PS 2). 👉#bicycle toxin conjugate (small peptide) targeting Nectin-4, with renal clearance (vs hepatic for EV). 👆Encouraging tolerability Matt Galsky Ignacio Duran Andrea Necchi



Excited to share our paper on AI-based prediction of disease progression in squamous skin cancers in npj Journals! Great collaboration w Juan Pisula & Kasia Bozek using federated learning & explainable AI for high accuracy while preserving patient privacy: nature.com/articles/s4169…

New NECTIN4 FISH probe now enables broader testing of NECTIN4 amplification across solid tumors! ➡️promising genomic biomarker for anti-NECTIN4 targeting therapies! 📈 NECTIN4 amp predicts response to: - Enfortumab vedotin in mUC Journal of Clinical Oncology 2024 - novel Bicycle-Drug Conjugate


NECTIN4 amplification predicts anti-Nectin4 therapy response! 🎯 NECTIN4 amp predicts: - Enfortumab vedotin response in mUC Journal of Clinical Oncology ASCO ascopubs.org/doi/full/10.12… & Zelenectide pevedotin (Bicycle-Drug Conjugate) response in TNBC SABCS + NSCLC-> now being tested in


The confirmed overall response rate with ABB-706 was 77% in patients with relapsed/refractory small cell lung cancer who received 2 prior lines of therapy. hubs.li/Q03JbwVr0 #SCLC #lcsm #WCLC25 | Lauren Averett Byers, MD


Now online in Cancer Discovery: EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis - by Alberto Diaz-Jimenez, Emily Shuldiner, Monte Winslow's Lab, Rocio Sotillo, and colleagues doi.org/10.1158/2159-8… DKFZ Stanford Medicine Stanford Cancer Institute


Sharing a paper below in Cell Genomics that took us literally 10 years+ (!) to write on the topics of 👇👇👇 * How, exactly, do we quantify viral mimicry - the expression of molecular features usually associated with nonself viruses by our own "self" cells? * Why do we see
